临床试验/IRCT20200105046010N5

IRCT20200105046010N5尚未招募未知

In- Vivo Bioequivalence study of Linagliptin / Metformin tablet 2.5/1000mg ABIDI (Liroprim 2.5/1000mg) with brand drugs (TRAJENTA® Duo 2.5/1000mg Boehringer Ingelheim, Gremany) in Iranian healthy volunteers.

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2020年7月13日

适应症

试验速览

阶段: 未知
状态: 尚未招募
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 60 years（—）
性别: All

入选标准

•General health(liver, heart, kidney)
•Body mass index(18-28)
•Informed consent
•Age(18-60)

排除标准

•A history of cardiovascular disease
•A history of liver & kidney disease
•Alcohol & Drug addiction
•Hypersensitivity to the drug

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Bioequivalence Study of Linagliptin/Metformin 2.5/1000 mg FC. Tablets of The Test Drug (Kharazmi Pharma, Iran)

IRCT20200105046010N101Kharazmi Pharmacy24

Study of Sitagliptine/ Metformin table In-Vivo Bioequivalence in healthy volunteersIn this study the bioequivalence of test and brand of Linagliptin tablets 5mg will evaluated..

IRCT20200105046010N12Razak Pharma24

igagliptin tablets 5mg ABIDI Pharmaceuticals (TRAJENTA® 5mg Tab) , In- Vivo Bioequivalence in Iranian healthy volunteers.

IRCT20200105046010N8Tabriz University of Medical Sciences24

Bioequivalence study of Linagliptin/metformin 2.5/1000 mg tabletThis study is performed on healthy volunteers and drug concentration in whole blood is determined..

IRCT20200623047902N38Actover Co.24

In-vivo Bioequivalence Test of Empagliflozin-Metformin tablets with brand drug (Synjardy® 25/1000 mg, Boehringer Ingelheim, Germany)Bio equivalence test.

IRCT20200105046010N60Pars Darou Pharmaceutical Company24